IRLAB Therapeutics ROE 2024

IRLAB Therapeutics Aktienanalyse

What does IRLAB Therapeutics do?

IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding IRLAB Therapeutics's Return on Equity (ROE)

IRLAB Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing IRLAB Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

IRLAB Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in IRLAB Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about IRLAB Therapeutics stock

What is the ROE (Return on Equity) of IRLAB Therapeutics this year?

The ROE of IRLAB Therapeutics this year is -1.54 undefined.

How has the Return on Equity (ROE) of IRLAB Therapeutics developed compared to the previous year?

The ROE of IRLAB Therapeutics has increased by 293.97% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of IRLAB Therapeutics?

A high ROE indicates that IRLAB Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of IRLAB Therapeutics?

A low ROE can indicate that IRLAB Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of IRLAB Therapeutics affect the company?

A change in ROE (Return on Equity) of IRLAB Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of IRLAB Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of IRLAB Therapeutics?

Some factors that can influence IRLAB Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does IRLAB Therapeutics pay?

Over the past 12 months, IRLAB Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRLAB Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of IRLAB Therapeutics?

The current dividend yield of IRLAB Therapeutics is .

When does IRLAB Therapeutics pay dividends?

IRLAB Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IRLAB Therapeutics?

IRLAB Therapeutics paid dividends every year for the past 0 years.

What is the dividend of IRLAB Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is IRLAB Therapeutics located?

IRLAB Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von IRLAB Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IRLAB Therapeutics from 10/6/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did IRLAB Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of IRLAB Therapeutics in the year 2023?

In the year 2023, IRLAB Therapeutics distributed 0 SEK as dividends.

In which currency does IRLAB Therapeutics pay out the dividend?

The dividends of IRLAB Therapeutics are distributed in SEK.